Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group

Lung Cancer

Volumn 58, Issue 3, 2007, Pages 355-361

  Pectasides, D ^a   Samantas, E ^b   Fountzilas, G ^c   Briasoulis, E ^d   Kosmidis, P ^e   Skarlos, D ^f   Dimopoulos, M A ^g   Kalofonos, H P ^h   Economopoulos, T ^a   Syrigos, K ^g  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^e HYGEIA HOSPITAL   (Greece)

^f HENRY DUNANT HOSPITAL   (Greece)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Cisplatin; Etoposide; Extensive small cell lung cancer; Irinotecan

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 35748983543     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.06.027     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Elias A.D. Small cell lung cancer: state-of-the-art therapy in 1996. Chest 112 4 Suppl (1997) 251S-258S
3. Sekine I., Nishiwaki Y., Kakinuma R., Kubota K., Hojo F., Matsumoto T., et al. Late recurrence of small-cell lung cancer: treatment and outcome. Oncology 53 4 (1996) 318-321
4. Evans W.K., Shepherd F.A., Feld R., Osoba D., Dang P., and Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3 11 (1985) 1471-1477
5. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83 12 (1991) 855-861
6. Roth B.J., Johnson D.H., Einhorn L.H., Schacter L.P., Cherng N.C., Cohen H.J., et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10 2 (1992) 282-291
7. Perez-Soler R., Glisson B.S., Lee J.S., Fossella F.V., Murphy W.K., Shin D.M., et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14 10 (1996) 2785-2790
8. Smit E.F., Fokkema E., Biesma B., Groen H.J., Snoek W., and Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77 2 (1998) 347-351
9. Glisson B.S., Kurie J.M., Perez-Soler R., Fox N.J., Murphy W.K., Fossella F.V., et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17 8 (1999) 2309-2315
10. Gridelli C., Manzione L., Perrone F., Veltri E., Cioffi R., Caprio M.G., et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 84 1 (2001) 38-41
11. Masuda N., Fukuoka M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10 8 (1992) 1225-1229
12. Kudoh S., Fujiwara Y., Takada Y., Yamamoto H., Kinoshita A., Ariyoshi Y., et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16 3 (1998) 1068-1074
13. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 2 (2002) 85-91
14. Briasoulis E., Samantas E., Kalofonos H., Skarlos D., Makatsoris T., Christodoulou C., et al. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. Cancer Chemother Pharmacol 56 5 (2005) 521-528
15. Sekine I., Nishiwaki Y., Noda K., Kudoh S., Fukuoka M., Mori K., et al. Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 14 5 (2003) 709-714
16. Yip D., and Harprer P.G. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 28 3 (2000) 173-185
17. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No 48). Geneva, Switzerland: World Health Organization; 1979.
18. Simon R., Wittes R.E., and Ellenberg S.S. Randomized phase II clinical trials. Cancer Treat Rep 69 12 (1985) 1375-1381
19. Ardizzoni A., Venturini M., Crino L., Sertoli M.R., Bruzzi P., Pennucci M.C., et al. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Eur J Cancer 29A 5 (1993) 687-692
20. Janssen-Heijnen M.L., Schipper R.M., Klinkhamer P.J., Crommelin M.A., and Coebergh J.W. Improvement and plateau in survival of small-cell lung cancer since 1975: a population-based study. Ann Oncol 9 5 (1998) 543-547
21. Lokich J., Anderson N., Moore C., Bern M., Coco F., Sonneborn H., et al. Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas. Eur J Cancer 34 5 (1998) 664-667
22. Lyss A.P., Herndon II J.E., Lynch Jr. T.J., Turrisi A.T., Watson D.M., Grethlein S.J., et al. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer 3 3 (2002) 205-210
23. Hainsworth J.D., Morrissey L.H., Scullin Jr. D.C., Houston G.A., Prasthofer E.F., Gray J.R., et al. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 94 9 (2002) 2426-2433
24. Masuda N., Matsui K., Negoro S., Takifuji N., Takeda K., Yana T., et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16 10 (1998) 3329-3334
25. Fujita A., Takabatake H., Tagaki S., and Sekine K. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology 59 2 (2000) 105-109
26. Kelly K., Lovato L., Bunn Jr. P.A., Livingston R.B., Zangmeister J., Taylor S.A., et al. Southwest Oncology Group. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Clin Cancer Res 7 8 (2001) 2325-2329
27. Boni C., Cocconi G., Bisagni G., Ceci G., and Peracchia G. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial. Cancer 63 4 (1989) 638-642
28. Kosmidis P.A., Samantas E., Fountzilas G., Pavlidis N., Apostolopoulou F., and Skarlos D. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 21 3 Suppl 6 (1994) 23-30
29. Glisson B.S., Kurie J.M., Perez-Soler R., Fox N.J., Murphy W.K., Fossella F.V., et al. etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17 8 (1999) 2309-2315
30. Schiller J.H., Adak S., Cella D., DeVore III R.F., and Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19 8 (2001) 2114-2122